Role of local Ayurveda therapy along with certain oral drug in the management of Presbyopia
- Conditions
- Health Condition 1: H524- Presbyopia
- Registration Number
- CTRI/2020/10/028381
- Lead Sponsor
- ational Institute of Ayurveda Jaipur
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
i) Patients willing to participate in this trial through written informed consent
ii) Patients who are 35 years of age and from either sex
ii) Patients having specific symptoms of prathama and dwitiya patalagata timira.
iii) Early to moderate presbyope determined by screening monocular best-corrected distant visual acuity (VA)
i) Patients with active ocular infection at visit 1 (bacterial, viral or fungal), positive history of an ocular herpetic infection, preauricular lymphadenopathy, or ongoing, active ocular inflammation (eg, moderate to severe blepharitis, allergic conjunctivitis, peripheral ulcerative keratitis, scleritis, uveitis), moderate to severe dry eye in either eye.
ii) Patients with clinically significant abnormal lens findings (eg cataract) including early lens changes and/or any evidence of media opacity in either eye
iii) Patients having intraocular pressure (IOP) that is less than 5 millimeters of mercury (mmHg) or greater than 22 mmHg in either eye documented at visit 1, or have a prior diagnosis of ocular hypertension or glaucoma or currently being treated with any type of topical IOP lowering (glaucoma) medication at visit 1.
iv) Patients who have abnormal findings on dilated fundus exam in either eye on visit 1 or a known history of retinal detachment or clinically significant retinal disease in either eye.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate and compare the efficacy of Bibhitakadi Ghrita Tarpana and Aystha Triphala with Ghrita as oral intake in the management of Timira w. s. r. to Presbyopia <br/ ><br>Timepoint: 45 days <br/ ><br>
- Secondary Outcome Measures
Name Time Method Any adverse event reported voluntarily, observed or enquire <br/ ><br>Timepoint: 45 days